Important Safety Information

  • The most common adverse reactions in clinical studies (≥ 3% of Aimovig-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig full Prescribing Information.


Indication

Aimovig is indicated for the preventive treatment of migraine in adults.
Aimovig Ally™ logo

Committed to helping your patients start and stay on Aimovig as prescribed

We are dedicated to supporting your patients taking Aimovig. Through personalized product services and support, we’ll help make the process seamless.
  • A seamless start

    Aimovig can be filled at your patient's pharmacy of choice, helping to make it simple for them to start treatment. In certain cases (eg, government or uninsured patients), you can fill out our Service Request Form to help patients get started and access Aimovig Ally product support services.

     
  • Ongoing product support

    We’re here to help ensure your patients and your staff have ongoing product support with Aimovig. Our support teams offer injection demonstrations, support in-office or over the phone, ongoing education, and more.

     
  • Access and financial resources for your patients

    With the Aimovig Ally Access Card,* patients with commercial insurance pay $5 per month. If insurance denies or requires prior authorization, patients can get Aimovig at no cost for up to 12 doses while insurance coverage is pursued. Eligibility criteria and program limits apply. We can also help identify other access resources available to your patients.

     
Download and provide patients with our Aimovig Ally Access Card brochure so they can enroll today
Ready to get started?

Simply call our Aimovig Ally support team at 833-AIMOVIG
(833-246-6844), Monday–Friday, 8 am–8 pm ET


Aimovig
free trial offer*
With the Aimovig™ Free Trial Offer,* patients can try 2 months of product at no cost to see if it is right for them. Eligibility criteria and program limits apply.

*Program details:
With the Aimovig Ally™ Access Card, an eligible commercially insured patient can receive one of the following two offers:

Terms and Conditions for copay offer: Pay a $5 copay per month, up to a maximum benefit of $2700 annually. Patient must be prescribed Aimovig™. Available if patient is commercially insured and 18 years or older. This offer is not valid if patient is receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. If at any time patient begins receiving coverage under any such federal-, state-, or government-funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. Patient may not seek reimbursement for value received from this offer from any third-party payers, including flexible spending accounts or healthcare savings accounts. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice. This is not health insurance. If you become aware that your health plan or pharmacy benefit manager does not allow the use of manufacturer copay support as part of your health plan design, you agree to comply with your obligations, if any, to disclose your use of the card to your insurer. This offer is ongoing and in order to remain eligible, patient must re-enroll every 12 months by visiting www.aimovigaccesscard.com/ or by calling 833-AIMOVIG (833-246-6844).

Terms and Conditions for Bridge to Commercial Coverage Offer Aimovig™ at no cost for up to 12 doses while insurance coverage is pursued. Patient must be prescribed Aimovig™ and have previously failed another preventive migraine treatment. Available if patient is commercially insured and 18 years or older. This offer is not valid if patient is receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD), or TRICARE or where prohibited by law. If at any time patient begins receiving coverage under any such federal-, state-, or government-funded healthcare program, patient will no longer be able to use this offer and patient must call 833-AIMOVIG to stop participation. Once insurance approval is obtained, patient is no longer eligible for this offer. Ongoing eligibility is subject to demonstrated efforts to pursue commercial coverage. No purchase necessary. This is not health insurance. Participation is not a guarantee of insurance coverage. Patient may be required to re-enroll. This offer is not renewable. Valid in the United States, Puerto Rico, and the US territories. Other restrictions may apply. This offer is subject to change or discontinuation without notice.

Ongoing eligibility for Bridge to Commercial Coverage Offer (Aimovig™ at no cost for up to 12 doses): Eligible patient must have commercial prescription insurance, a valid prescription for Aimovig™, previously failed another preventive migraine treatment, and participate in an insurance plan that requires a prior authorization or does not provide coverage for Aimovig™. Bridge to Commercial Coverage Offer provides up to 12 doses to patient while insurance coverage is pursued for up to 24 months from enrollment, whichever occurs first. Once insurance approval is obtained, patient is no longer eligible for the offer. Offer is not renewable. By participating in this offer, patient acknowledges intent to pursue insurance coverage for Aimovig™ with their healthcare provider. Ongoing eligibility requires that patient has (i) a prior authorization or medical exception denied within 90 days of first use of offer, and (ii) an appeal of the prior authorization or medical exception denied within 180 days of first use of offer. See full Terms and Conditions for more information.

Free trial is optional and available at no cost to patients new to Aimovig™. Patients are eligible to receive two doses of Aimovig™ dispensed directly from the Aimovig Ally™ Pharmacy. Doses are delivered on a monthly basis and will be coordinated with the patient. If the dose changes, please contact the Program. No purchase required. Patient may only redeem this offer once. This free trial is not health insurance and is not contingent on or a guarantee of insurance coverage. Trial product cannot be submitted for reimbursement under any healthcare program. Limitations may apply. Not available to residents of Massachusetts. Novartis Pharmaceuticals Corporation and Amgen reserve the right to rescind, revoke, or amend this offer without notice. Enrollment must occur by 12/31/2018.

Indication

Aimovig is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Please see Aimovig full Prescribing Information.